MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MBX - CA59501P1045 - Common Stock
0.24 CAD
0 (0%)
Taking everything into account, MBX scores 4 out of 10 in our fundamental rating. MBX was compared to 23 industry peers in the Biotechnology industry. While MBX seems to be doing ok healthwise, there are quite some concerns on its profitability. MBX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year MBX has reported negative net income.
- In the past year MBX has reported a negative cash flow from operations.
- The reported net income has been mixed in the past 5 years: MBX reported negative net income in multiple years.
- The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
1.2 Ratios
- MBX has a Return On Assets of -6.00%. This is amongst the best in the industry. MBX outperforms 86.96% of its industry peers.
- Looking at the Return On Equity, with a value of -8.08%, MBX belongs to the top of the industry, outperforming 86.96% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROIC | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- MBX's Gross Margin of 53.02% is amongst the best of the industry. MBX outperforms 82.61% of its industry peers.
- MBX's Gross Margin has improved in the last couple of years.
- The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
2. Health
2.1 Basic Checks
- MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for MBX has been increased compared to 1 year ago.
- MBX has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, MBX has a worse debt to assets ratio.
2.2 Solvency
- MBX has an Altman-Z score of 1.77. This is a bad value and indicates that MBX is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of MBX (1.77) is better than 86.96% of its industry peers.
- MBX has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
- MBX's Debt to Equity ratio of 0.24 is in line compared to the rest of the industry. MBX outperforms 56.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.77 |
ROIC/WACCN/A
WACC7.47%
2.3 Liquidity
- MBX has a Current Ratio of 8.48. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 8.48, MBX belongs to the top of the industry, outperforming 91.30% of the companies in the same industry.
- A Quick Ratio of 5.17 indicates that MBX has no problem at all paying its short term obligations.
- MBX has a Quick ratio of 5.17. This is amongst the best in the industry. MBX outperforms 86.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
- MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.28%.
- Looking at the last year, MBX shows a very negative growth in Revenue. The Revenue has decreased by -26.81% in the last year.
- Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 12.05% on average per year.
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
3.2 Future
- Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 52.75% on average per year.
- MBX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.96% yearly.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for MBX. In the last year negative earnings were reported.
- Based on the Price/Forward Earnings ratio of 5.94, the valuation of MBX can be described as very cheap.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 95.65% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of MBX to the average of the S&P500 Index (24.12), we can say MBX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 |
4.2 Price Multiples
- MBX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MBX is cheaper than 91.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 146.32 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MBX's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for MBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MBX (1/14/2026, 7:00:00 PM)
0.24
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-18 2025-12-18
Earnings (Next)02-11 2026-02-11
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.76%
Ins Owner ChangeN/A
Market Cap33.36M
Revenue(TTM)18.59M
Net Income(TTM)-2.25M
Analysts80
Price Target0.51 (112.5%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.94 | ||
| P/S | 1.79 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.2 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | 146.32 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY16.83%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.13
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% | ||
| FCFM | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 34.25 | ||
| Cap/Depr | 44.81% | ||
| Cap/Sales | 4.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 1.77 |
F-Score2
WACC7.47%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.85%
OCF growth 3YN/A
OCF growth 5YN/A
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.
What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.